SARC045

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients with Advanced Clear Cell Sarcoma

TYPE OF SARCOMA: Clear Cell Sarcoma
DRUG: Tebentafusp

ACCRUAL STATUS: Now recruiting patients

INVESTIGATORS:
Sandra D’Angelo, MD, Memorial Sloan Kettering Cancer Center
Andrea Napolitano, MD, Royal Marsden

CLINICALTRIALS.GOV IDENTIFIER: NCT06942442
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICAL TRIALS